Research advances in extrahepatic diseases associated with nonalcoholic fatty liver disease

Luying ZHU; Yuchen LI; Lihua DENG; Jingtong WANG

doi:10.3969/j.issn.1001-5256.2021.09.043

Volume 37 Issue 9

Sep. 2021

Turn off MathJax

Article Contents

Article Navigation > Journal of Clinical Hepatology > 2021 > 37(9): 2215-2219

PDF( 2181 KB)

Research advances in extrahepatic diseases associated with nonalcoholic fatty liver disease

DOI: 10.3969/j.issn.1001-5256.2021.09.043

Peking University People's Hospital & The Second Clinical Medical College of Peking University, Beijing 100044, China

Received Date: 2021-01-19
Accepted Date: 2021-02-18
Published Date: 2021-09-20

Abstract

Abstract

Nonalcoholic fatty liver disease (NAFLD) is a major cause of chronic liver diseases worldwide and covers a series of pathological manifestations from hepatic steatosis to inflammation, fibrosis, and even liver cirrhosis. NAFLD is associated with a wide range of extrahepatic diseases, including metabolic syndrome, cardiovascular disease, chronic kidney disease, endocrine diseases, obstructive sleep apnea-hypopnea syndrome, psoriasis, and skeleton-muscle diseases. The major causes of death in patients with NAFLD include cardiovascular disease, malignancies, and liver-related complications, suggesting that extrahepatic diseases associated with NAFLD should be taken seriously by clinicians. This article reviews the research advances in extrahepatic diseases associated with NAFLD, so as to provide ideas for clinical assessment and treatment.
- Non-alcoholic Fatty Liver Disease,
- Metabolic Syndrome X,
- Cardiovascular Diseases,
- Endocrine System Diseases,
- Kidney Diseases,
- Skin Diseases

FullText(HTML)

References(62)

References

[1]	YOUNOSSI ZM, KOENIG AB, ABDELATIF D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes[J]. Hepatology, 2016, 64(1): 73-84. DOI: 10.1002/hep.28431.
[2]	WU TF, LIAO XH, ZHONG BH. Epidemiology of nonalcoholic fatty liver disease in some regions of China[J]. J Clin Hepatol, 2020, 36(6): 1370-1373. DOI: 10.3969/j.issn.1001-5256.2020.06.039. 吴挺丰, 廖献花, 钟碧慧. 中国部分地区非酒精性脂肪肝病的流行情况[J]. 临床肝胆病杂志, 2020, 36(6): 1370-1373. DOI: 10.3969/j.issn.1001-5256.2020.06.039.
[3]	ZHOU F, ZHOU J, WANG W, et al. Unexpected rapid Increase in the burden of NAFLD in China from 2008 to 2018: A systematic review and Meta-analysis[J]. Hepatology, 2019, 70(4): 1119-1133. DOI: 10.1002/hep.30702.
[4]	ESTES C, ANSTEE QM, ARIAS-LOSTE MT, et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030[J]. J Hepatol, 2018, 69(4): 896-904. DOI: 10.1016/j.jhep.2018.05.036.
[5]	NAKAMURA A, YONEDA M, SUMIDA Y, et al. Modification of a simple clinical scoring system as a diagnostic screening tool for non-alcoholic steatohepatitis in Japanese patients with non-alcoholic fatty liver disease[J]. J Diabetes Investig, 2013, 4(6): 651-658. DOI: 10.1111/jdi.12101.
[6]	ESLAM M, NEWSOME PN, SARIN SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement[J]. J Hepatol, 2020, 73(1): 202-209. DOI: 10.1016/j.jhep.2020.03.039.
[7]	ESLAM M, SARIN SK, WONG VW, et al. The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease[J]. Hepatol Int, 2020, 14(6): 889-919. DOI: 10.1007/s12072-020-10094-2.
[8]	MENDEZ-SANCHEZ N, ARRESE M, GADANO A, et al. The Latin American Association for the Study of the Liver (ALEH) position statement on the redefinition of fatty liver disease[J]. Lancet Gastroenterol Hepatol, 2021, 6(1): 65-72. DOI: 10.1016/S2468-1253(20)30340-X.
[9]	ADAMS LA, LYMP JF, ST SAUVER J, et al. The natural history of nonalcoholic fatty liver disease: A population-based cohort study[J]. Gastroenterology, 2005, 129(1): 113-121. DOI: 10.1053/j.gastro.2005.04.014.
[10]	ONG JP, PITTS A, YOUNOSSI ZM. Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease[J]. J Hepatol, 2008, 49(4): 608-612. DOI: 10.1016/j.jhep.2008.06.018.
[11]	TARGHER G, BYRNE CD, LONARDO A, et al. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis[J]. J Hepatol, 2016, 65(3): 589-600. DOI: 10.1016/j.jhep.2016.05.013.
[12]	MANTOVANI A, DAURIZ M, SANDRI D, et al. Association between non-alcoholic fatty liver disease and risk of atrial fibrillation in adult individuals: An updated meta-analysis[J]. Liver Int, 2019, 39(4): 758-769. DOI: 10.1111/liv.14044.
[13]	ANSTEE QM, MANTOVANI A, TILG H, et al. Risk of cardiomyopathy and cardiac arrhythmias in patients with nonalcoholic fatty liver disease[J]. Nat Rev Gastroenterol Hepatol, 2018, 15(7): 425-439. DOI: 10.1038/s41575-018-0010-0.
[14]	KIM GA, LEE HC, CHOE J, et al. Association between non-alcoholic fatty liver disease and cancer incidence rate[J]. J Hepatol, 2017, 68(1): 140-146. DOI: 10.1016/j.jhep.2017.09.012.
[15]	HAMAGUCHI M, HASHIMOTO Y, OBORA A, et al. Non-alcoholic fatty liver disease with obesity as an independent predictor for incident gastric and colorectal cancer: A population-based longitudinal study[J]. BMJ Open Gastroenterol, 2019, 6(1): e000295. DOI: 10.1136/bmjgast-2019-000295.
[16]	MANTOVANI A, DAURIZ M, BYRNE CD, et al. Association between nonalcoholic fatty liver disease and colorectal tumours in asymptomatic adults undergoing screening colonoscopy: A systematic review and meta-analysis[J]. Metabolism, 2018, 87: 1-12. DOI: 10.1016/j.metabol.2018.06.004.
[17]	HUBER Y, LABENZ C, MICHEL M, et al. Tumor incidence in patients with non-alcoholic fatty liver disease[J]. Dtsch Arztebl Int, 2020, 117(43): 719-724. DOI: 10.3238/arztebl.2020.0719.
[18]	LEE JM, PARK YM, YUN JS, et al. The association between nonalcoholic fatty liver disease and esophageal, stomach, or colorectal cancer: National population-based cohort study[J]. PLoS One, 2020, 15(1): e0226351. DOI: 10.1371/journal.pone.0226351.
[19]	LIU SS, MA XF, ZHAO J, et al. Association between nonalcoholic fatty liver disease and extrahepatic cancers: A systematic review and meta-analysis[J]. Lipids Health Dis, 2020, 19(1): 118. DOI: 10.1186/s12944-020-01288-6.
[20]	WANG Z, ZHAO X, CHEN S, et al. Associations between nonalcoholic fatty liver disease and cancers in a large cohort in China[J]. Clin Gastroenterol Hepatol, 2021, 19(4): 788-796. e4. DOI: 10.1016/j.cgh.2020.05.009.
[21]	MUSSO G, GAMBINO R, TABIBIAN JH, et al. Association of non-alcoholic fatty liver disease with chronic kidney disease: A systematic review and meta-analysis[J]. PLoS Med, 2014, 11(7): e1001680. DOI: 10.1371/journal.pmed.1001680.
[22]	MANTOVANI A, ZAZA G, BYRNE CD, et al. Nonalcoholic fatty liver disease increases risk of incident chronic kidney disease: A systematic review and meta-analysis[J]. Metabolism, 2018, 79: 64-76. DOI: 10.1016/j.metabol.2017.11.003.
[23]	VILAR-GOMEZ E, CALZADILLA-BERTOT L, FRIEDMAN SL, et al. Improvement in liver histology due to lifestyle modification is independently associated with improved kidney function in patients with non-alcoholic steatohepatitis[J]. Aliment Pharmacol Ther, 2017, 45(2): 332-344. DOI: 10.1111/apt.13860.
[24]	BRZOZOWSKA MM, OSTAPOWICZ G, WELTMAN MD. An association between non-alcoholic fatty liver disease and polycystic ovarian syndrome[J]. J Gastroenterol Hepatol, 2009, 24(2): 243-247. DOI: 10.1111/j.1440-1746.2008.05740.x.
[25]	HOSSAIN N, STEPANOVA M, AFENDY A, et al. Non-alcoholic steatohepatitis (NASH) in patients with polycystic ovarian syndrome (PCOS)[J]. Scand J Gastroenterol, 2011, 46(4): 479-484. DOI: 10.3109/00365521.2010.539251.
[26]	ASFARI MM, SARMINI MT, BAIDOUN F, et al. Association of non-alcoholic fatty liver disease and polycystic ovarian syndrome[J]. BMJ Open Gastroenterol, 2020, 7(1): e000352. DOI: 10.1136/bmjgast-2019-000352.
[27]	SALVA-PASTOR N, LÓPEZ-SÁNCHEZ GN, CHÁVEZ-TAPIA NC, et al. Polycystic ovary syndrome with feasible equivalence to overweight as a risk factor for non-alcoholic fatty liver disease development and severity in Mexican population[J]. Ann Hepatol, 2020, 19(3): 251-257. DOI: 10.1016/j.aohep.2020.01.004.
[28]	CAI J, WU CH, ZHANG Y, et al. High-free androgen index is associated with increased risk of non-alcoholic fatty liver disease in women with polycystic ovary syndrome, independent of obesity and insulin resistance[J]. Int J Obes (Lond), 2017, 41(9): 1341-1347. DOI: 10.1038/ijo.2017.116.
[29]	MACUT D, TZIOMALOS K, BOŽIĆ-ANTIĆ I, et al. Non-alcoholic fatty liver disease is associated with insulin resistance and lipid accumulation product in women with polycystic ovary syndrome[J]. Hum Reprod, 2016, 31(6): 1347-1353. DOI: 10.1093/humrep/dew076.
[30]	TARANTO D, GUIMARÃES T, COUTO CA, et al. Nonalcoholic fatty liver disease in women with polycystic ovary syndrome: Associated factors and noninvasive fibrosis staging in a single Brazilian center[J]. Arch Endocrinol Metab, 2020, 64(3): 235-242. DOI: 10.20945/2359-3997000000242.
[31]	PAGADALA MR, ZEIN CO, DASARATHY S, et al. Prevalence of hypothyroidism in nonalcoholic fatty liver disease[J]. Dig Dis Sci, 2012, 57(2): 528-534. DOI: 10.1007/s10620-011-2006-2.
[32]	ESHRAGHIAN A, HAMIDIAN JAHROMI A. Non-alcoholic fatty liver disease and thyroid dysfunction: A systematic review[J]. World J Gastroenterol, 2014, 20(25): 8102-8109. DOI: 10.3748/wjg.v20.i25.8102.
[33]	CHUNG GE, KIM D, KIM W, et al. Non-alcoholic fatty liver disease across the spectrum of hypothyroidism[J]. J Hepatol, 2012, 57(1): 150-156. DOI: 10.1016/j.jhep.2012.02.027.
[34]	TAKAHASHI Y. The role of growth hormone and insulin-like growth factor-I in the liver[J]. Int J Mol Sci, 2017, 18(7): 1447. DOI: 10.3390/ijms18071447.
[35]	NISHIZAWA H, IGUCHI G, MURAWAKI A, et al. Nonalcoholic fatty liver disease in adult hypopituitary patients with GH deficiency and the impact of GH replacement therapy[J]. Eur J Endocrinol, 2012, 167(1): 67-74. DOI: 10.1530/EJE-12-0252.
[36]	LI M, XU Y, XU M, et al. Association between nonalcoholic fatty liver disease (NAFLD) and osteoporotic fracture in middle-aged and elderly Chinese[J]. J Clin Endocrinol Metab, 2012, 97(6): 2033-2038. DOI: 10.1210/jc.2011-3010.
[37]	UPALA S, JARUVONGVANICH V, WIJARNPREECHA K, et al. Nonalcoholic fatty liver disease and osteoporosis: A systematic review and meta-analysis[J]. J Bone Miner Metab, 2017, 35(6): 685-693. DOI: 10.1007/s00774-016-0807-2.
[38]	MANTOVANI A, DAURIZ M, GATTI D, et al. Systematic review with meta-analysis: Non-alcoholic fatty liver disease is associated with a history of osteoporotic fractures but not with low bone mineral density[J]. Aliment Pharmacol Ther, 2019, 49(4): 375-388. DOI: 10.1111/apt.15087.
[39]	FERNÁNDEZ-MINCONE T, CONTRERAS-BRICEÑO F, ESPINOSA-RAMÍREZ M, et al. Nonalcoholic fatty liver disease and sarcopenia: Pathophysiological connections and therapeutic implications[J]. Expert Rev Gastroenterol Hepatol, 2020, 14(12): 1141-1157. DOI: 10.1080/17474124.2020.1810563.
[40]	KIM G, LEE SE, LEE YB, et al. Relationship between relative skeletal muscle mass and nonalcoholic fatty liver disease: A 7-year longitudinal study[J]. Hepatology, 2018, 68(5): 1755-1768. DOI: 10.1002/hep.30049.
[41]	CAI C, SONG X, CHEN Y, et al. Relationship between relative skeletal muscle mass and nonalcoholic fatty liver disease: A systematic review and meta-analysis[J]. Hepatol Int, 2020, 14(1): 115-126. DOI: 10.1007/s12072-019-09964-1.
[42]	MESARWI OA, LOOMBA R, MALHOTRA A. Obstructive sleep apnea, hypoxia, and nonalcoholic fatty liver disease[J]. Am J Respir Crit Care Med, 2019, 199(7): 830-841. DOI: 10.1164/rccm.201806-1109TR.
[43]	MUSSO G, CASSADER M, OLIVETTI C, et al. Association of obstructive sleep apnoea with the presence and severity of non-alcoholic fatty liver disease. A systematic review and meta-analysis[J]. Obes Rev, 2013, 14(5): 417-431. DOI: 10.1111/obr.12020.
[44]	CHEN LD, CHEN MX, CHEN GP, et al. Association between obstructive sleep apnea and non-alcoholic fatty liver disease in pediatric patients: A meta-analysis[J]. Pediatr Obes, 2021, 16(3): e12718. DOI: 10.1111/ijpo.12718.
[45]	AGRAWAL S, DUSEJA A, AGGARWAL A, et al. Obstructive sleep apnea is an important predictor of hepatic fibrosis in patients with nonalcoholic fatty liver disease in a tertiary care center[J]. Hepatol Int, 2015, 9(2): 283-291. DOI: 10.1007/s12072-015-9615-3.
[46]	DAUDEN E, BLASCO AJ, BONANAD C, et al. Position statement for the management of comorbidities in psoriasis[J]. J Eur Acad Dermatol Venereol, 2018, 32(12): 2058-2073. DOI: 10.1111/jdv.15177.
[47]	NARAYANASAMY K, SANMARKAN AD, RAJENDRAN K, et al. Relationship between psoriasis and non-alcoholic fatty liver disease[J]. Prz Gastroenterol, 2016, 11(4): 263-269. DOI: 10.5114/pg.2015.53376.
[48]	GISONDI P, BARBA E, GIROLOMONI G. Non-alcoholic fatty liver disease fibrosis score in patients with psoriasis[J]. J Eur Acad Dermatol Venereol, 2016, 30(2): 282-287. DOI: 10.1111/jdv.13456.
[49]	ABEDINI R, SALEHI M, LAJEVARDI V, et al. Patients with psoriasis are at a higher risk of developing nonalcoholic fatty liver disease[J]. Clin Exp Dermatol, 2015, 40(7): 722-727. DOI: 10.1111/ced.12672.
[50]	van der VOORT EA, KOEHLER EM, DOWLATSHAHI EA, et al. Psoriasis is independently associated with nonalcoholic fatty liver disease in patients 55 years old or older: Results from a population-based study[J]. J Am Acad Dermatol, 2014, 70(3): 517-524. DOI: 10.1016/j.jaad.2013.10.044.
[51]	KOWDLEY KV, BELT P, WILSON LA, et al. Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease[J]. Hepatology, 2012, 55(1): 77-85. DOI: 10.1002/hep.24706.
[52]	NELSON JE, WILSON L, BRUNT EM, et al. Relationship between the pattern of hepatic iron deposition and histological severity in nonalcoholic fatty liver disease[J]. Hepatology, 2011, 53(2): 448-457. DOI: 10.1002/hep.24038.
[53]	SUMIDA Y, YONEDA M, HYOGO H, et al. A simple clinical scoring system using ferritin, fasting insulin, and type Ⅳ collagen 7S for predicting steatohepatitis in nonalcoholic fatty liver disease[J]. J Gastroenterol, 2011, 46(2): 257-268. DOI: 10.1007/s00535-010-0305-6.
[54]	BUGIANESI E, MCCULLOUGH AJ, MARCHESINI G. Insulin resistance: A metabolic pathway to chronic liver disease[J]. Hepatology, 2005, 42(5): 987-1000. DOI: 10.1002/hep.20920.
[55]	GUO L, TANG QQ. Research progress of the mechanism and therapy of non-alcoholic fatty liver disease[J]. Chin Bull Life Sci, 2018, 30(11): 1165-1172. DOI: 10.13376/j.cbls/2018141. 郭亮, 汤其群. 非酒精性脂肪肝发病机制和治疗的研究进展[J]. 生命科学, 2018, 30(11): 1165-1172. DOI: 10.13376/j.cbls/2018141.
[56]	ESLAM M, SANYAL AJ, GEORGE J. Toward more accurate nomenclature for fatty liver diseases[J]. Gastroenterology, 2019, 157(3): 590-593. DOI: 10.1053/j.gastro.2019.05.064.
[57]	TARGHER G, BYRNE CD, TILG H. NAFLD and increased risk of cardiovascular disease: Clinical associations, pathophysiological mechanisms and pharmacological implications[J]. Gut, 2020, 69(9): 1691-1705. DOI: 10.1136/gutjnl-2020-320622.
[58]	JULLIAN-DESAYES I, TAMISIER R, ZARSKI JP, et al. Impact of effective versus sham continuous positive airway pressure on liver injury in obstructive sleep apnoea: Data from randomized trials[J]. Respirology, 2016, 21(2): 378-385. DOI: 10.1111/resp.12672.
[59]	CHIN K, NAKAMURA T, TAKAHASHI K, et al. Effects of obstructive sleep apnea syndrome on serum aminotransferase levels in obese patients[J]. Am J Med, 2003, 114(5): 370-376. DOI: 10.1016/s0002-9343(02)01570-x.
[60]	GANZETTI G, CAMPANATI A, OFFIDANI A. Non-alcoholic fatty liver disease and psoriasis: So far, so near[J]. World J Hepatol, 2015, 7(3): 315-326. DOI: 10.4254/wjh.v7.i3.315.
[61]	CHEN LK, WOO J, ASSANTACHAI P, et al. Asian Working Group for Sarcopenia: 2019 consensus update on sarcopenia diagnosis and treatment[J]. J Am Med Dir Assoc, 2020, 21(3): 300-307. e2. DOI: 10.1016/j.jamda.2019.12.012.
[62]	PENG TC, WU LW, CHEN WL, et al. Nonalcoholic fatty liver disease and sarcopenia in a Western population (NHANES Ⅲ): The importance of sarcopenia definition[J]. Clin Nutr, 2019, 38(1): 422-428. DOI: 10.1016/j.clnu.2017.11.021.

Relative Articles

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Tables(1)

Get Citation

PDF

XML

Article Metrics

Article views (1067) PDF downloads(99)

Research advances in extrahepatic diseases associated with nonalcoholic fatty liver disease

DOI: 10.3969/j.issn.1001-5256.2021.09.043

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Research advances in extrahepatic diseases associated with nonalcoholic fatty liver disease

DOI: 10.3969/j.issn.1001-5256.2021.09.043

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content